These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16369311)

  • 1. Escitalopram in adolescent major depression.
    Schaller JL; Rawlings DB
    MedGenMed; 2005 Jan; 7(1):6. PubMed ID: 16369311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
    Sanchez C; Reines EH; Montgomery SA
    Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escitalopram: a review of its use in the management of major depressive disorder in adults.
    Garnock-Jones KP; McCormack PL
    CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which SSRIs most effectively treat depression in adolescents?
    DeLucia V; Kelsberg G; Safranek S
    J Fam Pract; 2016 Sep; 65(9):632-4. PubMed ID: 27672691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 8. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Escitalopram for treatment of major depressive disorder in adults].
    Llorca PM; Brousse G; Schwan R
    Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
    Kennedy SH; Andersen HF; Thase ME
    Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
    Strawn JR; Poweleit EA; Ramsey LB
    J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
    [No Abstract]   [Full Text] [Related]  

  • 13. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
    Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C
    J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
    Peselow ED; Tobia G; Karamians R; Pizano D; IsHak WW
    Psychiatry Res; 2015 Feb; 225(3):680-6. PubMed ID: 25496869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
    Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
    Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
    Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
    Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A target trial emulation comparing the antidepressant effectiveness of selective serotonin reuptake inhibitors (SSRIs) highlighting the importance of patent-related confounding by indication.
    Rohde C; Hieronymus F; Østergaard SD
    Acta Psychiatr Scand; 2024 Oct; 150(4):198-208. PubMed ID: 38994727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population.
    Kaplan C; Zhang Y
    J Ment Health Policy Econ; 2012 Dec; 15(4):171-8. PubMed ID: 23525835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.